Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Evaluation of the echinocandin antifungal mk-0991 (l-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Abruzzo, G. K.
  • Flattery, A. M.
  • Gill, C. J.
  • Kong, L.
  • Smith, J. G.
  • Pikounis, V. B.
  • Balkovec, J. M.
  • Bouffard, A. F.
  • Dropinski, J. F.
  • Rosen, Hugh
  • Kropp, H.
  • Bartizal, K.

publication date

  • November 1997

journal

  • Antimicrobial Agents and Chemotherapy  Journal

abstract

  • The in vivo activity of the Merck antifungal echinocandin drug candidate MK-0991 (L-743,872) was evaluated in mouse models of disseminated candidiasis, aspergillosis, and cryptococcosis. The echinocandins are potent inhibitors of 1,3-beta-D-glucan synthase. Two models of disseminated candidiasis were used. In a Candida albicans mouse survival model with both DBA/2N and CD-1 mice, estimates of the 50% effective doses (ED50s) of MK-0991 were 0.04 and 0.10 mg/kg of body weight/dose at 21 days after challenge, respectively. In a C. albicans target organ assay (TOA) with DBA/2N mice, MK-0991 at levels of > or =0.09 mg/kg/dose significantly reduced the numbers of C. albicans CFU/g of kidneys compared to the numbers in the kidneys of control mice from 1 to 28 days after challenge. Even when given as a single intraperitoneal dose either 30 min or 24 h after challenge, MK-0991 was effective and significantly reduced the numbers of C. albicans CFU/g of kidney compared to those in the controls. MK-0991 was >300-fold less active when it was administered orally than when it was administered parenterally. MK-0991 was efficacious in mouse TOAs against other C. albicans strains and Candida species including Candida tropicalis, Candida (Torulopsis) glabrata, Candida lusitaniae, Candida parapsilosis, and Candida krusei. MK-0991 was ineffective against disseminated Cryptococcus neoformans infections. In the model of disseminated aspergillosis in mice, MK-0991 at doses of > or =0.02 mg/kg/dose significantly prolonged the survival of DBA/2N mice, with estimates of the ED50 and ED90 of MK-0991 being 0.03 and 0.12 mg/kg/dose, respectively, at 28 days after challenge. MK-0991 is a potent, parenterally administered therapeutic agent against disseminated candidiasis and aspergillosis that warrants further investigation in human clinical trials.

subject areas

  • Administration, Oral
  • Animals
  • Anti-Bacterial Agents
  • Antifungal Agents
  • Aspergillosis
  • Candidiasis
  • Cryptococcosis
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Echinocandins
  • Female
  • Injections, Intraperitoneal
  • Kidney Diseases
  • Mice
  • Mice, Inbred DBA
  • Peptides
  • Peptides, Cyclic
scroll to property group menus

Identity

PubMed Central ID

  • PMC164124

International Standard Serial Number (ISSN)

  • 0066-4804

PubMed ID

  • 9371329
scroll to property group menus

Additional Document Info

start page

  • 2333

end page

  • 2338

volume

  • 41

issue

  • 11

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support